Beta Bionics, Inc. $BBNX Stock Sold by Engineers Gate Manager LP

Key Points

• Engineers Gate Manager LP cut its Beta Bionics stake by 91.3% in the second quarter, selling 124,535 shares and retaining 11,808 shares valued at approximately $185,000.
• Analyst sentiment remains broadly positive, with Beta Bionics receiving a “Moderate Buy” consensus rating and a $22.91 average price target; Truist and Wells Fargo both set $28 targets.
• The company faces significant investor uncertainty from securities-fraud lawsuits alleging inadequate disclosure of FDA concerns and device complaints, while recent insider stock sales add to caution despite some transactions occurring under 10b5-1 plans.

Engineers Gate Manager LP decreased its position in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) by 91.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,808 shares of the company's stock after selling 124,535 shares during the period. Engineers Gate Manager LP's holdings in Beta Bionics were worth $185,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BBNX. Caitong International Asset Management Co. Ltd raised its stake in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock worth $61,000 after purchasing an additional 1,818 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $62,000. ProShare Advisors LLC acquired a new position in Beta Bionics in the fourth quarter worth approximately $217,000. The Manufacturers Life Insurance Company acquired a new position in Beta Bionics in the second quarter worth approximately $172,000. Finally, Values First Advisors Inc. raised its position in Beta Bionics by 35.1% during the first quarter. Values First Advisors Inc. now owns 47,551 shares of the company's stock valued at $476,000 after acquiring an additional 12,360 shares in the last quarter.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Truist Financial raised its price target on Beta Bionics to $28 from $23 and maintained a “Buy” rating, implying meaningful upside from recent trading levels. Wells Fargo also initiated coverage with an “Overweight” rating and a $28 target, while other analysts have recently raised their targets. Truist Financial rating
• Neutral Sentiment: Multiple law firms publicized a securities class action against Beta Bionics on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lead-plaintiff deadline is November 3, 2026; the repeated notices are mostly informational but increase attention on the company’s legal situation. Kaplan Fox class action notice
• Negative Sentiment: The lawsuits allege that Beta Bionics failed to adequately disclose FDA concerns, including a 2025 Form 483 and more than 18,000 iLet-related complaints. The allegations link later disclosures about FDA compliance and device safety to a sharp share-price decline. They have not been proven, but could create financial, operational and reputational uncertainty. BFA Law BBNX investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but it nevertheless adds to investor caution. SEC insider sale filing

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX opened at $21.51 on Monday. The stock's 50-day moving average is $18.17 and its 200-day moving average is $14.44. The company has a market cap of $967.73 million, a P/E ratio of -13.04 and a beta of 3.37. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, equities analysts predict that Beta Bionics, Inc. will post -2.06 EPS for the current year.

Insider Transactions at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the sale, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 2,650 shares of the business's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the transaction, the insider owned 177,390 shares in the company, valued at approximately $3,902,580. The trade was a 1.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 97,327 shares of company stock worth $1,900,019. 5.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. UBS Group reissued a "buy" rating and issued a $25.00 target price on shares of Beta Bionics in a research report on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. William Blair assumed coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a "market perform" rating for the company. The Goldman Sachs Group raised their target price on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Finally, Wall Street Zen raised Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday, September 19th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Beta Bionics currently has an average rating of "Moderate Buy" and a consensus price target of $22.91.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.